HPG-1860 is under clinical development by Hepagene Therapeutics Shanghai and currently in Phase I for Primary Sclerosing Cholangitis. According to GlobalData, Phase I drugs for Primary Sclerosing Cholangitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HPG-1860 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HPG-1860 overview
HPG-1860 is under development for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (primary biliary cirrhosis), primary sclerosing cholangitis and inflammatory bowel disease. It is administered by oral route. The drug candidate is a avermectin derivative and acts by targeting farnesoid X activated receptor.
Hepagene Therapeutics Shanghai overview
Hepagene Therapeutics Shanghai., a liver disease drug developer, and focusing on the research and development of innovative drugs for liver disease. The company is headquartered China.
For a complete picture of HPG-1860’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.